Oric Pharmaceuticals
Jared Moore is an experienced professional in the field of medicinal chemistry, currently serving as Associate Director at ORIC Pharmaceuticals Inc. since January 2017, where previous roles included Principal Scientist, Senior Scientist, and Scientist. Prior to this, Jared held a postdoctoral researcher position in the Stoltz Laboratory at Caltech from January 2015 to November 2016 and completed graduate studies at UC Davis from July 2009 to December 2014 in the Shaw Laboratory, earning a Doctor of Philosophy in Organic Chemistry. In addition, Jared gained industry experience as an intern in Medicinal Chemistry at Genentech during a 14-week program in 2013. Educational qualifications include a Ph.D. in Organic Chemistry from the University of California, Davis, and a Bachelor of Science in Chemistry from California Polytechnic State University-San Luis Obispo.
This person is not in the org chart
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.